Clinical trial · Interventional
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
High Dose Chemotherapy And Autologous Peripheral Blood Stem Cell Rescue For High Risk Acute Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation and interleukin-2 in treating patients who have acute leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aldesleukin | Biological | Aldesleukin | ALIAS |
| busulfan | Drug | Busulfan | ALIAS |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| filgrastim | Biological | Filgrastim | ALIAS |
| melphalan | Drug | Melphalan | ALIAS |
| peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed acute leukemia
* High-risk due to any of the following:
* Cytogenetic abnormalities involving 5q, 7q, 8q, 11q23, or t(9;22)
* WBC greater than 100,000/mm3
* Prior myelodysplastic syndrome
* Complete remission (CR) lasting less than 12 months
* No favorable cytogenetic parameters (e.g., t(15;17), inv16, or t(8;21))
* CR following standard anti-leukemic therapy confirmed by bone marrow evaluation
* Second and third CR allowed
* Ineligible for higher priority national or institutional study or allogeneic peripheral blood stem cell transplantation
PATIENT CHARACTERISTICS:
Age:
* Any age
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* See Disease Characteristics
Hepatic:
* Bilirubin less than 1.5 times normal
* SGOT or SGPT less than 1.5 times normal
Renal:
* Creatinine less than 1.5 times normal
Cardiovascular:
* LVEF at least 45% if receiving cyclophosphamide
* Normal electrocardiogram OR
* Approval by cardiologist
Pulmonary:
* DLCO less than 60% predicted OR
* Approval by pulmonologist
Other:
* Not pregnant or nursing
* No concurrent illness that would preclude study
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* Not specified
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* Not specifiedReferences
Publications (0)
Data not yet available